Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Wednesday 01 November, 2006

XTL Biopharm Ltd

XTL to Present at the Rodman & Renshaw Conf...

                   XTL Biopharmaceuticals to Present at the                    
                     Rodman & Renshaw Healthcare Conference                     

NEW YORK, NEW YORK, November 1, 2006 - XTL Biopharmaceuticals Ltd. (NASDAQ:
XTLB; LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the Company's
Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 8th
Annual Healthcare Conference. Mr. Bentsur's presentation will take place on
Monday, November 6, 2006 at 10:15 am EST at the New York Palace Hotel in New
York City.

A live webcast of Mr. Bentsur's presentation will be available at An archived version of the webcast
will be available following the conclusion of the live presentation.


XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of infectious diseases,
with a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule,
non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is
currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL
is also developing XTL-6865 - a combination of two monoclonal antibodies
against the hepatitis C virus - presently in Phase 1 clinical trials in
patients with chronic hepatitis C. XTL's hepatitis C pipeline also includes
several families of pre-clinical hepatitis C small molecule inhibitors.  XTL
also has an active in-licensing and acquisition program designed to identify
and acquire additional drug candidates. XTL is publicly traded on the NASDAQ,
London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).


Ron Bentsur, Chief Executive Officer

Tel: +1-(212)-531-5960


a d v e r t i s e m e n t